Verastem, Inc. (VSTM)
7.21
-0.17
(-2.30%)
USD |
NASDAQ |
Aug 28, 13:08
Verastem Free Cash Flow : -171.82M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -171.82M |
| March 31, 2026 | -160.57M |
| December 31, 2025 | -147.13M |
| September 30, 2025 | -140.93M |
| June 30, 2025 | -120.23M |
| March 31, 2025 | -115.15M |
| December 31, 2024 | -104.80M |
| September 30, 2024 | -109.38M |
| June 30, 2024 | -102.18M |
| March 31, 2024 | -94.50M |
| December 31, 2023 | -86.46M |
| September 30, 2023 | -73.40M |
| June 30, 2023 | -71.89M |
| March 31, 2023 | -64.68M |
| December 31, 2022 | -63.67M |
| September 30, 2022 | -56.99M |
| June 30, 2022 | -52.74M |
| March 31, 2022 | -53.46M |
| December 31, 2021 | -53.70M |
| September 30, 2021 | -65.47M |
| June 30, 2021 | -11.66M |
| March 31, 2021 | -20.81M |
| December 31, 2020 | -35.30M |
| September 30, 2020 | -51.26M |
| June 30, 2020 | -122.09M |
| Date | Value |
|---|---|
| March 31, 2020 | -134.19M |
| December 31, 2019 | -138.96M |
| September 30, 2019 | -120.76M |
| June 30, 2019 | -116.03M |
| March 31, 2019 | -92.25M |
| December 31, 2018 | -76.02M |
| September 30, 2018 | -76.90M |
| June 30, 2018 | -65.62M |
| March 31, 2018 | -69.21M |
| December 31, 2017 | -57.31M |
| September 30, 2017 | -42.94M |
| June 30, 2017 | -37.14M |
| March 31, 2017 | -29.35M |
| December 31, 2016 | -29.52M |
| September 30, 2016 | -33.78M |
| June 30, 2016 | -39.34M |
| March 31, 2016 | -44.67M |
| December 31, 2015 | -45.77M |
| September 30, 2015 | -45.78M |
| June 30, 2015 | -44.87M |
| March 31, 2015 | -41.97M |
| December 31, 2014 | -39.33M |
| September 30, 2014 | -35.67M |
| June 30, 2014 | -32.08M |
| March 31, 2014 | -29.31M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Ironwood Pharmaceuticals, Inc. | 185.55M |
| Dianthus Therapeutics, Inc. | -155.71M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| Anika Therapeutics, Inc. | 0.562M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -43.91M |
| Cash from Investing (Quarterly) | 16.25M |
| Cash from Financing (Quarterly) | -1.539M |
| Free Cash Flow Per Share (Quarterly) | -0.4386 |
| Free Cash Flow to Equity (Quarterly) | -42.76M |
| Free Cash Flow to Firm (Quarterly) | -43.54M |
| Free Cash Flow Yield | -26.85% |